Meeting to be held in New York on October 8-9 hosted by Piper Sandler.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX:
- Optimistic Buy Rating for Tenax Therapeutics Driven by Strong Patent Portfolio and Market Potential of Levosimendan
- Tenax announces EPO intention to grant patent for levosimendan in PH-HFpEF
- Tenax Therapeutics Expands Licensing Agreement with Orion
- Promising Potential of Tenax Therapeutics’ TNX-103 Drives Buy Rating Amid Positive Phase 2 Results and Anticipated Phase 3 Trial
- Tenax Therapeutics initiated with an Overweight at Piper Sandler